| Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation (NCT04781855) | M.D. Anderson Cancer Center | 2022-07-14 |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (NCT04995536) | City of Hope Medical Center | 2021-07-27 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633) | Fred Hutchinson Cancer Center | 2021-01-25 |
| Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study (NCT04230304) | Mayo Clinic | 2020-11-11 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma (NCT04578600) | Joseph Tuscano | 2020-10-23 |
| Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL (NCT03639324) | Virginia Commonwealth University | 2020-10-02 |
| Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT04169737) | M.D. Anderson Cancer Center | 2020-07-29 |
| CD19-Specific T Cells Post AlloSCT (NCT03579888) | M.D. Anderson Cancer Center | 2020-06-26 |
| Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT03961672) | City of Hope Medical Center | 2020-05-13 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor (NCT03884972) | M.D. Anderson Cancer Center | 2019-06-18 |
| Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial (NCT03003546) | Mayo Clinic | 2019-04-25 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (NCT03479268) | City of Hope Medical Center | 2018-04-27 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729) | Fred Hutchinson Cancer Center | 2017-12-05 |
| Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL (NCT03045328) | Steven E. Coutre | 2017-09-26 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma (NCT03010358) | Alexey Danilov, MD | 2017-07-17 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (NCT02568553) | National Cancer Institute (NCI) | 2016-11-15 |
| Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia (NCT02756897) | M.D. Anderson Cancer Center | 2016-07-07 |
| Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT02225275) | M.D. Anderson Cancer Center | 2016-03-31 |
| Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT02614508) | Emory University | 2016-01-01 |
| Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation (NCT02420912) | M.D. Anderson Cancer Center | 2015-06-19 |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas (NCT02332980) | Mayo Clinic | 2015-02-19 |
| Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma (NCT01995669) | M.D. Anderson Cancer Center | 2014-05-27 |
| Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (NCT02160015) | National Cancer Institute (NCI) | 2014-05-20 |
| Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia (NCT01865617) | Fred Hutchinson Cancer Center | 2013-05-22 |
| NK Cells in Cord Blood Transplantation (NCT01619761) | M.D. Anderson Cancer Center | 2013-05-03 |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01886859) | National Cancer Institute (NCI) | 2013-04-26 |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma (NCT01381692) | National Cancer Institute (NCI) | 2011-07-20 |
| Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia (NCT01008462) | Fred Hutchinson Cancer Center | 2010-03-18 |
| Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer (NCT00789776) | Fred Hutchinson Cancer Center | 2008-10-13 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (NCT00723099) | Fred Hutchinson Cancer Center | 2008-06-25 |
| Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma (NCT00005803) | Fred Hutchinson Cancer Center | 1999-09-01 |